Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.

Frau J, Saccà F, Signori A, Baroncini D, Fenu G, Annovazzi P, Capobianco M, Signoriello E, Laroni A, La Gioia S, Sartori A, Maniscalco GT, Bonavita S, Clerico M, Russo CV, Gallo A, Lapucci C, Carotenuto A, Sormani MP, Cocco E; i-MuST study group.

J Neurol. 2019 Jun 17. doi: 10.1007/s00415-019-09424-8. [Epub ahead of print]

PMID:
31209573
2.

Right phrenic nerve palsy following transcatheter radiofrequency current atrial fibrillation ablation: Case report.

Abbadessa G, Lavorgna L, Cirillo G, Clerico M, Todisco V, Cirillo M, Trojsi F, Tedeschi G, Bonavita S.

J Int Med Res. 2019 May 30:300060519849267. doi: 10.1177/0300060519849267. [Epub ahead of print]

PMID:
31144560
3.

Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS.

Lavie C, Rollot F, Durand-Dubief F, Marignier R, Ionescu I, Casey R, Moreau T, Tourniaire P, Hutchinson M, D'Hooghe MB, Laplaud DA, Clavelou P, De Sèze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Durelli L, Clerico M, Trojano M, Patti F, Vukusic S; PRIMS and POPARTMUS investigators.

Mult Scler. 2019 Apr;25(4):591-600. doi: 10.1177/1352458518763080. Epub 2018 Mar 20.

PMID:
31081475
4.

Oral prolonged-release Oxycodone-Naloxone: analgesic response, safety profile, and factors influencing the response in advanced cancer patients.

Corli O, Iorno V, Legramandi L, Rulli E, Roberto A, Azzarello G, Schiavon S, Cavanna L, De Santis S, Cartoni C, Di Marco P, Dauri M, Mistretta R, Bortolussi R, Clerico M, Pacchioni M, Crispino C, Marabese M, Corsi N; GREAT Collaborators.

Pain Pract. 2019 Mar 27. doi: 10.1111/papr.12784. [Epub ahead of print]

PMID:
30917409
5.

Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer.

Fornaro L, Vivaldi C, Parnofiello A, Ugolini C, Aprile G, De Maglio G, Pecora I, Iacono D, Crivelli F, Catanese S, Cardellino GG, Lencioni M, Vasile E, Salani F, Clerico M, Calvetti L, Falcone A, Fasola G, Fontanini G, Montagnani F.

Br J Cancer. 2019 Mar;120(5):522-526. doi: 10.1038/s41416-019-0399-4. Epub 2019 Feb 12.

PMID:
30745584
6.

Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis.

Iannello A, Rolla S, Maglione A, Ferrero G, Bardina V, Inaudi I, De Mercanti S, Novelli F, D'Antuono L, Cardaropoli S, Todros T, Turrini MV, Cordioli C, Puorro G, Marsili A, Lanzillo R, Brescia Morra V, Cordero F, De Bortoli M, Durelli L, Visconti A, Cutrupi S, Clerico M.

Front Immunol. 2019 Jan 8;9:3075. doi: 10.3389/fimmu.2018.03075. eCollection 2018.

7.

Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey.

Lavorgna L, Esposito S, Lanzillo R, Sparaco M, Ippolito D, Cocco E, Fenu G, Borriello G, De Mercanti S, Frau J, Capuano R, Trojsi F, Rosa L, Clerico M, Laroni A, Morra VB, Tedeschi G, Bonavita S.

J Neurol. 2019 Mar;266(3):707-716. doi: 10.1007/s00415-019-09193-4. Epub 2019 Jan 16.

PMID:
30649617
8.

Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.

Vernieri C, Galli F, Ferrari L, Marchetti P, Lonardi S, Maiello E, Iaffaioli RV, Zampino MG, Zaniboni A, De Placido S, Banzi M, Damiani A, Ferrari D, Rosati G, Labianca RF, Bidoli P, Frassineti GL, Nicolini M, Pavesi L, Tronconi MC, Buonadonna A, Ferrario S, Re GL, Adamo V, Tamburini E, Clerico M, Giordani P, Leonardi F, Barni S, Ciarlo A, Cavanna L, Gori S, Cinieri S, Faedi M, Aglietta M, Antista M, Dotti KF, Galli F, Di Bartolomeo M; TOSCA (Three or Six Colon Adjuvant) Investigators.

Oncologist. 2019 Mar;24(3):385-393. doi: 10.1634/theoncologist.2018-0442. Epub 2019 Jan 3.

PMID:
30606884
9.

A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study.

Gagno S, D'Andrea MR, Mansutti M, Zanusso C, Puglisi F, Dreussi E, Montico M, Biason P, Cecchin E, Iacono D, Russo S, Cinausero M, Saracchini S, Gasparini G, Sartori D, Bari M, Collovà E, Meo R, Merkabaoui G, Spagnoletti I, Pellegrino A, Gianni L, Sandri P, Cretella E, Vattemi E, Rocca A, Serra P, Fabbri MA, Benedetti G, Foghini L, Medici M, Basso U, Amoroso V, Riccardi F, Baldelli AM, Clerico M, Bonura S, Saggia C, Innocenti F, Toffoli G.

Clin Breast Cancer. 2019 Apr;19(2):137-145.e4. doi: 10.1016/j.clbc.2018.11.009. Epub 2018 Nov 24.

10.

e-Health and multiple sclerosis: An update.

Lavorgna L, Brigo F, Moccia M, Leocani L, Lanzillo R, Clerico M, Abbadessa G, Schmierer K, Solaro C, Prosperini L, Tedeschi G, Giovannoni G, Bonavita S.

Mult Scler. 2018 Nov;24(13):1657-1664. doi: 10.1177/1352458518799629. Epub 2018 Sep 19.

PMID:
30231004
11.

Fake news, influencers and health-related professional participation on the Web: A pilot study on a social-network of people with Multiple Sclerosis.

Lavorgna L, De Stefano M, Sparaco M, Moccia M, Abbadessa G, Montella P, Buonanno D, Esposito S, Clerico M, Cenci C, Trojsi F, Lanzillo R, Rosa L, Morra VB, Ippolito D, Maniscalco G, Bisecco A, Tedeschi G, Bonavita S.

Mult Scler Relat Disord. 2018 Oct;25:175-178. doi: 10.1016/j.msard.2018.07.046. Epub 2018 Jul 31.

PMID:
30096683
12.

Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study.

Saccà F, Lanzillo R, Signori A, Maniscalco GT, Signoriello E, Lo Fermo S, Repice A, Annovazzi P, Baroncini D, Clerico M, Binello E, Cerqua R, Mataluni G, Bonavita S, Lavorgna L, Zarbo IR, Laroni A, Rossi S, Pareja Gutierrez L, La Gioia S, Frigeni B, Barcella V, Frau J, Cocco E, Fenu G, Torri Clerici V, Sartori A, Rasia S, Cordioli C, Di Sapio A, Pontecorvo S, Grasso R, Barrilà C, Russo CV, Esposito S, Ippolito D, Bovis F, Gallo F, Sormani MP; ; On behalf of the iMUST Group.

Mult Scler. 2018 Jul 25:1352458518790390. doi: 10.1177/1352458518790390. [Epub ahead of print]

PMID:
30044207
13.

Conflict of interest among Italian medical oncologists: a national survey.

DeCensi A, Numico G, Ballatori E, Artioli F, Clerico M, Fioretto L, Livellara V, Ruggeri B, Tomirotti M, Verusio C, Roila F; Italian College of Chief Medical Oncologists (CIPOMO).

BMJ Open. 2018 Jun 30;8(6):e020912. doi: 10.1136/bmjopen-2017-020912.

14.

Long-term survival after liver metastasectomy in gastric cancer: Systematic review and meta-analysis of prognostic factors.

Montagnani F, Crivelli F, Aprile G, Vivaldi C, Pecora I, De Vivo R, Clerico MA, Fornaro L.

Cancer Treat Rev. 2018 Sep;69:11-20. doi: 10.1016/j.ctrv.2018.05.010. Epub 2018 May 17. Review.

PMID:
29860024
15.

Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses.

Rolla S, De Mercanti SF, Bardina V, Horakova D, Habek M, Adamec I, Cocco E, Annovazzi P, Vladic A, Novelli F, Durelli L, Clerico M.

J Neuroimmunol. 2017 Dec 15;313:89-91. doi: 10.1016/j.jneuroim.2017.10.009. Epub 2017 Oct 17.

16.

Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study.

Laroni A, Signori A, Maniscalco GT, Lanzillo R, Russo CV, Binello E, Lo Fermo S, Repice A, Annovazzi P, Bonavita S, Clerico M, Baroncini D, Prosperini L, La Gioia S, Rossi S, Cocco E, Frau J, Torri Clerici V, Signoriello E, Sartori A, Zarbo IR, Rasia S, Cordioli C, Cerqua R, Di Sapio A, Lavorgna L, Pontecorvo S, Barrilà C, Saccà F, Frigeni B, Esposito S, Ippolito D, Gallo F, Sormani MP; iMUST group.

Neurology. 2017 Nov 28;89(22):2222-2229. doi: 10.1212/WNL.0000000000004686. Epub 2017 Nov 1.

PMID:
29093064
17.

Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.

Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF, Durelli L.

Expert Opin Drug Saf. 2017 Aug;16(8):963-972. doi: 10.1080/14740338.2017.1346082. Epub 2017 Jul 5. Review.

PMID:
28641055
18.

Natalizumab in Multiple Sclerosis: Long-Term Management.

Clerico M, Artusi CA, Liberto AD, Rolla S, Bardina V, Barbero P, Mercanti SF, Durelli L.

Int J Mol Sci. 2017 Apr 29;18(5). pii: E940. doi: 10.3390/ijms18050940. Review.

19.

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.

Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.

Cochrane Database Syst Rev. 2017 Apr 25;4:CD012200. doi: 10.1002/14651858.CD012200.pub2. Review.

20.

Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.

Clerico M, De Mercanti S, Artusi CA, Durelli L, Naismith RT.

Mult Scler. 2017 May;23(6):874-876. doi: 10.1177/1352458516688350. Epub 2017 Feb 1.

PMID:
28290755
21.

Parametric method for the noise risk assessment of professional orchestral musicians.

Bo M, Clerico M, Pognant F.

Noise Health. 2016 Nov-Dec;18(85):319-328. doi: 10.4103/1463-1741.195797.

22.

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea.

Barbero P, Busso M, Artusi CA, De Mercanti S, Tinivella M, Veltri A, Durelli L, Clerico M.

J Vis Exp. 2016 Nov 9;(117). doi: 10.3791/54606.

23.

Influence of cigarette smoking on ALS outcome: a population-based study.

Calvo A, Canosa A, Bertuzzo D, Cugnasco P, Solero L, Clerico M, De Mercanti S, Bersano E, Cammarosano S, Ilardi A, Manera U, Moglia C, Marinou K, Bottacchi E, Pisano F, Mora G, Mazzini L, Chiò A.

J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1229-1233. doi: 10.1136/jnnp-2016-313793. Epub 2016 Sep 21.

PMID:
27656044
24.

Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study.

Lugaresi A, De Robertis F, Clerico M, Brescia Morra V, Centonze D, Borghesan S, Maniscalco GT; RIVER study group.

Expert Opin Drug Deliv. 2016 Jul;13(7):931-5. doi: 10.1517/17425247.2016.1148029. Epub 2016 Feb 24.

PMID:
26909646
25.

Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.

De Mercanti S, Rolla S, Cucci A, Bardina V, Cocco E, Vladic A, Soldo-Butkovic S, Habek M, Adamec I, Horakova D, Annovazzi P, Novelli F, Durelli L, Clerico M.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 21;3(1):e194. doi: 10.1212/NXI.0000000000000194. eCollection 2016 Feb. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2016 Aug;3(4):e273.

26.

Use of a checklist to improve pain control in hospitalized cancer patients: the 38Checkpain project.

Gentili M, Clerico M, Spizzichino M, Fanelli G.

Future Oncol. 2016 Jan;12(2):199-205. doi: 10.2217/fon.15.291. Epub 2015 Dec 8.

PMID:
26643066
27.

Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia.

Barbero P, Busso M, Tinivella M, Artusi CA, De Mercanti S, Cucci A, Veltri A, Avagnina P, Calvo A, Chio' A, Durelli L, Clerico M.

J Neurol. 2015 Dec;262(12):2662-7. doi: 10.1007/s00415-015-7894-1. Epub 2015 Sep 26.

PMID:
26410746
28.

Normal saline versus heparin solution to lock totally implanted venous access devices: Results from a multicenter randomized trial.

Dal Molin A, Clerico M, Baccini M, Guerretta L, Sartorello B, Rasero L.

Eur J Oncol Nurs. 2015 Dec;19(6):638-43. doi: 10.1016/j.ejon.2015.04.001. Epub 2015 Apr 29.

PMID:
25933709
29.

Therapeutic education to cancer patients: experiences of Italian nurses.

Prandi C, Garrino L, Clerico M, Sommovigo T, Vellone E, Alvaro R.

Prof Inferm. 2014 Oct-Dec;67(4):243-51. doi: 10.7429/pi.2014.674235.

PMID:
25837480
30.

Epigenetic therapy for Friedreich ataxia.

Soragni E, Miao W, Iudicello M, Jacoby D, De Mercanti S, Clerico M, Longo F, Piga A, Ku S, Campau E, Du J, Penalver P, Rai M, Madara JC, Nazor K, O'Connor M, Maximov A, Loring JF, Pandolfo M, Durelli L, Gottesfeld JM, Rusche JR.

Ann Neurol. 2014 Oct;76(4):489-508. doi: 10.1002/ana.24260. Epub 2014 Sep 16.

31.

Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β.

Rolla S, Bardina V, De Mercanti S, Quaglino P, De Palma R, Gned D, Brusa D, Durelli L, Novelli F, Clerico M.

J Leukoc Biol. 2014 Dec;96(6):1155-64. doi: 10.1189/jlb.5A0813-463RR. Epub 2014 Aug 5.

PMID:
25097195
32.

Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study.

Chiò A, Calvo A, Bovio G, Canosa A, Bertuzzo D, Galmozzi F, Cugnasco P, Clerico M, De Mercanti S, Bersano E, Cammarosano S, Ilardi A, Manera U, Moglia C, Sideri R, Marinou K, Bottacchi E, Pisano F, Cantello R, Mazzini L, Mora G; Piemonte and Valle d’Aosta Register for Amyotrophic Lateral Sclerosis.

JAMA Neurol. 2014 Sep;71(9):1134-42. doi: 10.1001/jamaneurol.2014.1129.

33.

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).

Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L.

JAMA Neurol. 2014 Aug;71(8):954-60. doi: 10.1001/jamaneurol.2014.1200.

PMID:
24977406
34.

Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.

Lugaresi A, Florio C, Brescia-Morra V, Cottone S, Bellantonio P, Clerico M, Centonze D, Uccelli A, di Ioia M, De Luca G, Marcellusi A, Paolillo A; BRIDGE study group.

BMC Neurol. 2012 Mar 5;12:7. doi: 10.1186/1471-2377-12-7.

35.

Th17 cells in multiple sclerosis express higher levels of JAK2, which increases their surface expression of IFN-γR2.

Conti L, De Palma R, Rolla S, Boselli D, Rodolico G, Kaur S, Silvennoinen O, Niccolai E, Amedei A, Ivaldi F, Clerico M, Contessa G, Uccelli A, Durelli L, Novelli F.

J Immunol. 2012 Feb 1;188(3):1011-8. doi: 10.4049/jimmunol.1004013. Epub 2012 Jan 4.

36.

The late complications of totally implantable central venous access ports: the results from an Italian multicenter prospective observation study.

Dal Molin A, Rasero L, Guerretta L, Perfetti E, Clerico M.

Eur J Oncol Nurs. 2011 Dec;15(5):377-81. doi: 10.1016/j.ejon.2010.11.007. Epub 2010 Dec 16.

PMID:
21167777
37.

Pro-inflammatory cytokine and chemokine mRNA blood level in multiple sclerosis is related to treatment response and interferon-beta dose.

Cucci A, Barbero P, Clerico M, Ferrero B, Versino E, Contessa G, Demercanti S, Viglietta E, Di Liberto A, Vai AG, Durelli L.

J Neuroimmunol. 2010 Sep 14;226(1-2):150-7. doi: 10.1016/j.jneuroim.2010.05.038. Epub 2010 Jun 23.

PMID:
20573405
38.

Prevalence, incidence and types of mild anemia in the elderly: the "Health and Anemia" population-based study.

Tettamanti M, Lucca U, Gandini F, Recchia A, Mosconi P, Apolone G, Nobili A, Tallone MV, Detoma P, Giacomin A, Clerico M, Tempia P, Savoia L, Fasolo G, Ponchio L, Della Porta MG, Riva E.

Haematologica. 2010 Nov;95(11):1849-56. doi: 10.3324/haematol.2010.023101. Epub 2010 Jun 9.

39.

Immediate loading of full-arch fixed prostheses supported by axial and tilted implants for the treatment of edentulous atrophic mandibles.

Agliardi E, Clericò M, Ciancio P, Massironi D.

Quintessence Int. 2010 Apr;41(4):285-93.

PMID:
20305862
40.

Immediate rehabilitation of the edentulous jaws with full fixed prostheses supported by four implants: interim results of a single cohort prospective study.

Agliardi E, Panigatti S, Clericò M, Villa C, Malò P.

Clin Oral Implants Res. 2010 May;21(5):459-65. doi: 10.1111/j.1600-0501.2009.01852.x. Epub 2010 Jan 22.

PMID:
20105197
41.

Sex differences in hip morphology: is stem modularity effective for total hip replacement?

Traina F, De Clerico M, Biondi F, Pilla F, Tassinari E, Toni A.

J Bone Joint Surg Am. 2009 Nov;91 Suppl 6:121-8. doi: 10.2106/JBJS.I.00533. No abstract available.

PMID:
19884419
42.

Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.

Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Lepore V, Livrea P, Comi G, Amato MP; Italian Multiple Sclerosis Database Network (MSDN) Group.

Ann Neurol. 2009 Oct;66(4):513-20. doi: 10.1002/ana.21757.

PMID:
19847899
43.

Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.

Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Portaccio E, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Iaffaldano P, Direnzo V, D'Onghia M, Lepore V, Livrea P, Comi G, Amato MP; Italian Multiple Sclerosis Database Network Group.

J Neurol Sci. 2009 Nov 15;286(1-2):109-13. doi: 10.1016/j.jns.2009.06.036. Epub 2009 Jul 16.

PMID:
19615696
44.

T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.

Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, Ferrero B, Eid P, Novelli F.

Ann Neurol. 2009 May;65(5):499-509. doi: 10.1002/ana.21652.

PMID:
19475668
45.

Risk factors for tumor occurrence in patients with myasthenia gravis.

Citterio A, Beghi E, Millul A, Evoli A, Mantegazza R, Antozzi C, Baggi F, Cornelio F, Durelli L, Clerico M, Piccolo G, Cosi V.

J Neurol. 2009 Aug;256(8):1221-7. doi: 10.1007/s00415-009-5091-9. Epub 2009 Mar 29.

PMID:
19330280
46.

Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1b.

Durelli L, Barbero P, Cucci A, Ferrero B, Ricci A, Contessa G, De Mercanti S, Ripellino P, Lapuma D, Viglietta E, Bergui M, Versino E, Clerico M; OPTIMS Trial NAb Sub-Study Group.

Expert Opin Biol Ther. 2009 Apr;9(4):387-97. doi: 10.1517/14712590902762781 .

PMID:
19278300
47.

Association of mild anemia with hospitalization and mortality in the elderly: the Health and Anemia population-based study.

Riva E, Tettamanti M, Mosconi P, Apolone G, Gandini F, Nobili A, Tallone MV, Detoma P, Giacomin A, Clerico M, Tempia P, Guala A, Fasolo G, Lucca U.

Haematologica. 2009 Jan;94(1):22-8. doi: 10.3324/haematol.13449. Epub 2008 Nov 10.

48.

The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.

Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Ferrero B, Rivoiro C, Ferrero C, Picco E, Ripellino P, Viglietti D, Giuliani G, Montanari E, Clerico M; OPTIMS Study Group.

J Neurol. 2008 Sep;255(9):1315-23. doi: 10.1007/s00415-008-0879-6. Epub 2008 Sep 25.

PMID:
18825438
49.

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Clerico M, Faggiano F, Palace J, Rice G, Tintorè M, Durelli L.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005278. doi: 10.1002/14651858.CD005278.pub3. Review.

PMID:
18425915
50.

Association of mild anemia with cognitive, functional, mood and quality of life outcomes in the elderly: the "Health and Anemia" study.

Lucca U, Tettamanti M, Mosconi P, Apolone G, Gandini F, Nobili A, Tallone MV, Detoma P, Giacomin A, Clerico M, Tempia P, Guala A, Fasolo G, Riva E.

PLoS One. 2008 Apr 2;3(4):e1920. doi: 10.1371/journal.pone.0001920.

Supplemental Content

Loading ...
Support Center